Hangzhou Alltest Biotech Co., Ltd. (SHA:688606)
China flag China · Delayed Price · Currency is CNY
43.61
-0.55 (-1.25%)
Nov 17, 2026, 3:00 PM CST

Hangzhou Alltest Biotech Income Statement

Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Operating Revenue
879.59899.45862.37752.263,3871,873
Other Revenue
5.95.94.222.441.470.86
885.49905.34866.58754.73,3891,873
Revenue Growth
0.44%4.47%14.82%-77.73%80.88%64.98%
Cost of Revenue
464.18448.35392.82380.661,563843.87
Gross Profit
421.31456.99473.77374.041,8261,030
Selling, General & Admin
151.88159.06120.23135.87228.482.48
Research & Development
131.57109.3295.82121.17207.395.46
Other Operating Expenses
31.189.299.246.6627.559.87
Operating Expenses
315.37280.85233.17275.02471.08191.89
Operating Income
105.94176.14240.699.011,354837.67
Interest Expense
-0.27-0.28-0.42-1.46-2.17-0.67
Interest & Investment Income
15.9725.8345.6654.26744.86
Currency Exchange Gain (Loss)
-12.95-12.955.8515.8531.74-18.28
Other Non Operating Income (Expenses)
-42.85-1.830.81-1.330.73-3.95
EBT Excluding Unusual Items
65.85186.92292.51166.281,452859.63
Impairment of Goodwill
-----14.01-
Gain (Loss) on Sale of Investments
32.3440.6135.5532.67-15.2221.33
Gain (Loss) on Sale of Assets
0.040.61.22-0.660.52-0.08
Asset Writedown
-1---0.28-60.7-
Other Unusual Items
22.3323.0518.44-0.5719.1114.65
Pretax Income
119.56251.18347.71197.441,381895.53
Income Tax Expense
6.6131.144.817.16195.99129.84
Earnings From Continuing Operations
112.95220.07302.91180.281,185765.69
Minority Interest in Earnings
0.390.12-0.440.3-0.54-
Net Income
113.33220.19302.47180.581,185765.69
Net Income to Common
113.33220.19302.47180.581,185765.69
Net Income Growth
-61.55%-27.20%67.50%-84.76%54.75%12.73%
Shares Outstanding (Basic)
777979797975
Shares Outstanding (Diluted)
777979797975
Shares Change
-2.53%0.03%-0.02%-0.07%5.96%25.16%
EPS (Basic)
1.472.783.822.2814.9510.24
EPS (Diluted)
1.472.783.822.2814.9510.24
EPS Growth
-60.55%-27.22%67.54%-84.75%46.05%-9.93%

Additional Metrics

Fiscal Year
TTMFY 2025FY 2024FY 2023FY 2022FY 2021
Period Ending
Sep '26 Dec '25 Dec '24 Dec '23 Dec '22 Dec '21
Free Cash Flow
61.65-12.5108.87-508.731,090783.75
Free Cash Flow Per Share
0.80-0.161.38-6.4213.7610.48
Dividend Per Share
1.0002.0003.0001.5006.7572.703
Dividend Growth
-60.00%-33.33%100.00%-77.80%150.00%99.99%
Gross Margin
47.58%50.48%54.67%49.56%53.87%54.96%
Operating Margin
11.96%19.46%27.76%13.12%39.97%44.71%
Profit Margin
12.80%24.32%34.90%23.93%34.97%40.87%
Free Cash Flow Margin
6.96%-1.38%12.56%-67.41%32.18%41.84%
EBITDA
155.75215.68266.44120.181,378846.45
EBITDA Margin
17.59%23.82%30.75%15.92%40.65%45.18%
D&A For EBITDA
49.8139.5325.8421.1723.118.78
EBIT
105.94176.14240.699.011,354837.67
EBIT Margin
11.96%19.46%27.76%13.12%39.97%44.71%
Effective Tax Rate
5.53%12.38%12.88%8.69%14.19%14.50%
Revenue as Reported
885.49905.34866.58754.73,3891,873